Completed PHASE2 INTERVENTIONAL NCT00002522

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (CEP) WITH RESCUE BY AUTOLOGOUS BONE MARROW OR AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN'S DISEASE

Sponsor: Temple University

Conditions Lymphoma

Interventions autologous bone marrow transplantation bone marrow ablation with stem cell support cisplatin cyclophosphamide etoposide peripheral blood stem cell transplantation radiation therapy syngeneic bone marrow transplantation

Updated 5 times since 2017 Last updated: Sep 30, 2010 Started: Feb 28, 1993 Primary completion: Feb 28, 2002 Completion: Feb 28, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002522, this PHASE2 trial focuses on Lymphoma and remains completed. Sponsored by Temple University, it has been updated 5 times since 1993, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Temple University

Data source: Temple University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States